Pharmaceuticals
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of JWATM214 in patients with advanced hepato...
2023-02-28 17:30
4189
Chula's AICute - An Assessment Tool for Ischemic Stroke Risk
A research team from the Faculty of Medicine and Faculty of Engineering, Chulalongkorn University has jointly developed AICute, an innovative program to assess the chance of stroke caused by heart disease (Ischemic Stroke), aimed at helping hospitals that lack cardiologists to enhance the effecti...
2023-02-28 12:24
4036
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
2023-02-28 09:16
4055
CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
* This supplementary new drug application was filed for the fourth indication for sugemalimab inChina, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If approved, sugemalimab would be the first PD-L1 monoclo...
2023-02-28 08:05
6332
Innovent Announces First Participant Dosed in Phase 1 Clinical Study of IBI333 (VEGF-A/VEGF-C Bispecific Fusion Protein) in Patients with Neovascular Age-related Macular Degeneration
ROCKVILLE, Md. and SUZHOU, China, Feb. 28, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-02-28 08:00
5719
Everest Medicines Hosts Ceremony to Celebrate Commencement of Operations at its State-of-the-Art mRNA Vaccine Manufacturing Facility
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today held a ceremony to celebrate the initiation of operations a...
2023-02-28 07:30
6772
Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index
HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective from March 13, 2023. HSHKBIO selects securities of multiple listed co...
2023-02-27 17:15
4656
Turacoz Paves the Way in Digital Content Management for Healthcare Communications with Veeva & Expert Training
UTRECHT, Netherlands and NEW DELHI, Feb. 27, 2023 /PRNewswire/ -- As digital
content gains importance in healthcare, the medical writing industry is
transitioning to digital content management.
2023-02-27 17:07
2424
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the financial year ended31 December 2022. All figures are in AU$ unless otherwise stated. 2022 HIGHLIGHTS * Total Group revenue $160.1M ...
2023-02-27 14:37
2961
Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
* Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval inEurope * The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ -- Servier, a global pharmaceutical company, today announ...
2023-02-24 21:29
3463
HAVAS HEALTH & YOU AND THE AMERICAN PARKINSON DISEASE ASSOCIATION LAUNCH SEXUAL WELLNESS CAMPAIGN PARKINSEX
Activation Advances Nonclinical Strategies for People with Parkinson's to Deepen Intimacy NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Parkinson's disease affects more than ten million people worldwide and the prevalence of sexual dysfunction is disproportionately high in patients, causing partners t...
2023-02-23 22:15
3025
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China
SAN DIEGO, Feb. 23, 2023 /PRNewswire/ -- Today, Invivoscribe announced that its Shanghai lab in China has received CAP accreditation. The College of American Pathologists (CAP) is a professional organization that accredits clinical laboratories across the world. The CAP accreditation process is ...
2023-02-23 22:00
3809
TB Alliance Announces David Norton as Board Chair
NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The TB Alliance Board of Directors has electedDavid Norton as Chairperson of the Board. In this role, David will provide leadership to a diverse Board committed to advancing the vision of TB Alliance. "David Norton has contributed greatly to TB Alliance's ...
2023-02-23 22:00
2970
Xspray Pharma Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL)
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymp...
2023-02-23 15:02
2420
Lepu Biopharma and Keymed Jointly Announces Global Exclusive Licence Agreement with AstraZeneca for CMG901
HONG KONG, Feb. 22, 2023 /PRNewswire/ -- Lepu Biopharma Co., Ltd. (Stock Code: 02157.HK) and Keymed Biosciences Inc., ("Keymed") (Stock Code: 02162 HK) today jointly announces a global exclusive licence agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for CMG901, a potential first-in-class Claudi...
2023-02-23 12:26
3574
Dawn Health partners with leading pharmaceutical company to transform chronic care
COPENHAGEN, Denmark, Feb. 23, 2023 /PRNewswire/ -- Dawn Health, a global leader in digital health, today announced a strategic partnership with Novartis, one of the leading medicines companies in the world, to support the development of a platform that enables the effective remote monitoring and ...
2023-02-23 12:16
2176
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
TOKYO, Feb. 22, 2023 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the development of a new enzyme for double strand oligonucleotide formation with high productivity...
2023-02-22 21:05
3663
CRT 2023 selects Syntach Cardiac Support System for Best Innovation Competition
LUND, Sweden, Feb. 22, 2023 /PRNewswire/ -- Syntach AB ("Syntach") is pleased to announce that the Company's Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting taking place at the ...
2023-02-22 20:22
3532
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication – NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, an...
2023-02-21 23:04
4248
New Study Shows GlycoMark® Test Identifies Prediabetic Individuals with the Highest Risk of Developing Diabetes Before Symptoms Develop
RALEIGH, N.C., Feb. 21, 2023 /PRNewswire/ -- A new study indicates that the GlycoMark blood test identifies high-risk, asymptomatic patients with prediabetes, not detected by standard diabetes tests, hemoglobin A1C and glucose – a critical clinical need, as physicians can identify those patients...
2023-02-21 20:30
2455
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21Nuix Neo Generative AI Framework
[Picked up by 262 media titles]
2026-10-08 08:02Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
13030
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
10754
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
10369
